Lumena Files For $75 Million IPO To Forward Liver Disease Drugs
This article was originally published in The Pink Sheet Daily
Executive Summary
Biotech investment momentum may have slowed recently, but the San Diego biotech is hoping the IPO window remains open. The company is developing a compound shelved by Pfizer to address high cholesterol; LUM001 currently is in Phase II for a set of cholestatic liver diseases.
You may also be interested in...
Lumena Pharmaceuticals Takes $23M To Fight Rare Liver Disease
The San Diego start-up will use its Series A round to continue development on a pair of drugs for cholestatic liver disease. Once studied by Pfizer and Sanofi to fight high cholesterol but shelved years ago as statins proved more effective, the drugs show promise in orphan indications.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.